RUA RUA Life Sciences plc

0.2568USD19.50 GBp · LSE-11.36%Mkt Cap: 15.94M USDP/E: —

RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufactu…

Key Statistics

Company
Market Cap15.94M USD
Enterprise Value13.73M USD
Revenue (TTM)6.08M USD
Gross Profit2.34M USD
Net Income (TTM)-1.90M USD
Revenue/Share0.10 USD
Last Price0.2568 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees59
CountryGB
SectorHealthcare
IndustryMedical Devices
ISINGB0033360586
Valuation
P/E (Trailing)—
P/E (Forward)-48.75
PEG—
EV/EBITDA18.13
EV/Revenue2.26
P/S2.62
P/B1.73
EPS (TTM)0.00 USD
EPS (Forward)-0.0053 USD
52W Range
0.151441% of range0.4082
52W High0.4082 USD
52W Low0.1514 USD
Profitability
Gross Margin81.06%
Oper. Margin2.94%
EBITDA Margin12.45%
Profit Margin-65.72%
ROE-20.05%
ROA-17.63%
ROIC-38.25%
ROCE-25.65%
Growth
Revenue Growth6.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.75M USD
CapEx (TTM)72.43K USD
FCF Margin—
FCF Yield—
Net Debt-2.26M USD
Net Debt/EBITDA-2.98
Net Debt/FCF—
Balance Sheet
Debt/Equity0.05
Current Ratio5.92
Quick Ratio4.44
Book Value/Sh0.15 USD
Cash/Share0.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateSep 1, 2003
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.6584 USD
Upside (mean)+156.4%
Target Range0.6584 USD – 0.6584 USD
# Analysts1
Ownership
Shares Out.62.06M
Float50.42M
Insiders19.16%
Institutions17.58%
Technical
SMA 500.3582 (-28.3%)
SMA 2000.2841 (-9.6%)
Beta0.98
S&P 52W Chg12.00%
Avg Vol (30d)168.50K
Avg Vol (10d)237.04K
Technical Indicators
RSI (14)22.7
MACD-1.8297
MACD Signal-1.3353
MACD Hist.-0.4944
BB Upper0.4059 USD
BB Middle0.3286 USD
BB Lower0.2512 USD
BB Width47.09%
ATR (14)0.0242 USD
Vol Ratio (20d)1.77x

About RUA Life Sciences (LON: RUA)

›

RUA Life Sciences (LON: RUA) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 59 employees.

The shares were at 19.50 GBp on 19 November 2026, up 56.0% over 52 weeks. Its 52-week range is 11.50 GBp to 31.00 GBp: the price is 37.1% below the high and 69.6% above the low.

Its market capitalisation is 12.10M GBP.

RUA Life Sciences reports return on equity of -20.1%, an operating margin of 2.9% and revenue up 6.1% year over year.

It holds more cash than debt, a net cash position of 1.71M GBP. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 50.00 GBp is 156.4% above the current price.